https://scholars.lib.ntu.edu.tw/handle/123456789/604455
標題: | Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study | 作者: | Gianni, L CHIUN-SHENG HUANG Egle, D Bermejo, B Zamagni, C Thill, M Anton, A Zambelli, S Bianchini, G Russo, S Ciruelos, E M Greil, R Semiglazov, V Colleoni, M Kelly, C Mariani, G Del Mastro, L Maffeis, I Valagussa, P Viale, G |
關鍵字: | atezolizumab; neoadjuvant therapy; triple-negative breast cancer | 公開日期: | 17-二月-2022 | 來源出版物: | Annals of oncology : official journal of the European Society for Medical Oncology | 摘要: | High-risk triple-negative breast cancers (TNBCs) are characterized by poor prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy, thus representing an area in need of new therapeutic approaches. Programmed death-ligand 1 (PD-L1) expression is an adaptive mechanism of tumour resistance to tumour-infiltrating lymphocytes, which in turn are needed for response to chemotherapy. Overall, available data support the concept that blockade of PD-L1/programmed cell death protein 1 checkpoint may improve efficacy of classical chemotherapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/604455 | ISSN: | 09237534 | DOI: | 10.1016/j.annonc.2022.02.004 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。